# US 2014/0154244 A1 · Methods of Treating Primary Brain Tumors by Administering Letrozole

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154244 A1
- Document ID: US20140154244A1
- Status: Published application
- Kind: A1
- Application number: 14/096,536
- Filed: 2013-12-04
- Published: 2014-06-05
- Earliest claimed: 2012-12-04
- Assignees: University of Cincinnati
- Applicants: University of Cincinnati
- Inventors: Pankaj Desai; Nimita Dave
- Web page: https://patentgrep.com/patent/US20140154244A1

## CPC

- A61K 31/4196: 1,2,4-Triazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to the field of cancer treatment, and more specifically to the field of treatment of primary malignant brain tumors. Provided herein are methods of treating primary brain tumors, including gliomas, by administering to a patient in need thereof a therapeutically effective amount of the aromatase inhibitor letrozole.

## Claims

### Claim 1

A method of treating a primary brain tumor comprising administering to a patient in need thereof a therapeutically effective amount of letrozole.

### Claim 2 (depends on 1)

The method of claim 1, wherein the primary brain tumor is selected from the group consisting of glioma, meningeal tumor, medulloblastoma, and schwannoma.

### Claim 3 (depends on 2)

The method of claim 2, wherein the primary brain tumor is a glioma selected from the group consisting of astrocytoma, oligodendroma, and ependymoma.

### Claim 4 (depends on 3)

The method of claim 3, wherein the glioma is an astrocytoma selected from the group consisting of Grade I, Grade II, Grade III, and Grade IV.

### Claim 5 (depends on 2)

The method of claim 2, wherein the primary brain tumor is a meningeal tumor selected from the group consisting of meningioma, atypical meningioma, anaplastic meningioma, hemangiopericytoma, anaplastic hemangiopericytoma, and hemangioblastoma.

### Claim 6 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount comprises a daily dose of from about 2.5 mg to about 60 mg.

### Claim 7 (depends on 1)

The method of claim 1, wherein letrozole is administered orally, intravenously, or directly to the tumor.

### Claim 8 (depends on 7)

The method of claim 7, wherein letrozole is administered orally.

### Claim 9 (depends on 1)

The method of claim 1, wherein letrozole crosses the blood brain barrier.

### Claim 10 (depends on 1)

The method of claim 1, wherein letrozole crosses the blood tumor barrier.

### Claim 11 (depends on 1)

The method of claim 1, further comprising administering one or more second active agents to the patient.

### Claim 12 (depends on 11)

The method of claim 11, wherein the second active agent is selected from the group consisting of a chemotherapeutic agent, an anti-inflammatory agent, an immunosuppressive agent, and a corticosteroid.

### Claim 13 (depends on 12)

The method of claim 12, wherein the second active agent is a chemotherapeutic agent selected from the group consisting of an alkylating agent, a platinum drug, an antimetabolite, an anti-tumor antibiotic, a topoisomerase inhibitor, a mitotic inhibitor, a targeted therapy, an anti-angiogenic compound, a differentiating agent, and a hormone therapy.

### Claim 14 (depends on 12)

The method of claim 12, wherein the chemotherapeutic agent is selected from the group consisting of temozolamide, bevacuzimab, and carmustine.

### Claim 15 (depends on 11)

The method of claim 11, wherein the one or more second active agent is co-administered with letrozole.

### Claim 16 (depends on 1)

The method of claim 1, further comprising administering a tumor treating field (TTF) therapy to the patient.

### Claim 17 (depends on 1)

The method of claim 1, further comprising administering radiation therapy to the patient.

### Claim 18 (depends on 1)

The method of claim 1, wherein administering comprises administering letrozole before, during, or after a surgery to remove the brain tumor.

### Claim 19

A method of treating a primary brain tumor in a patient comprising:
(a) obtaining a biopsy of the primary brain tumor;
(b) analyzing the biopsy to determine whether the primary brain tumor is a type of tumor that is responsive to letrozole treatment; and
(c) administering a therapeutic amount of letrozole to the patient when the primary brain tumor is determined to be a type of tumor that is responsive to letrozole treatment.